Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report issued on Monday.

A number of other equities analysts also recently commented on ABEO. Oppenheimer assumed coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Abeona Therapeutics Trading Down 0.2 %

Shares of ABEO opened at $4.99 on Monday. The firm’s fifty day moving average is $5.43 and its two-hundred day moving average is $5.82. The stock has a market cap of $216.92 million, a PE ratio of -1.86 and a beta of 1.79. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $8.45.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19. Research analysts forecast that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at $151,000. Citigroup Inc. raised its holdings in Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 56,332 shares during the period. Western Standard LLC lifted its position in Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares during the last quarter. Jane Street Group LLC purchased a new position in Abeona Therapeutics during the third quarter worth about $84,000. Finally, XTX Topco Ltd acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at about $160,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.